Mr. Herper wrote earlier today on what September in Munich may mean to Vytorin (full SEAS trial data) -- tonight, he's writing about the lack of outcomes data for Vytorin. Does Matt know that something major is about to break on this ongoing debacle?
I dunno. Do read all of his latest -- here's a snippet:
. . . .In SEAS, Vytorin failed to do better than placebo at treating a heart valve disease called aortic stenosis, but it did reduce the risk of heart attacks, strokes and operations to unclog arteries. But the results weren't much better than what you'd expect from Zocor alone. . . .
What does Matt suspect, that we've haven't yet puzzled out? Hmmmm. . . . Thoughts?
No comments:
Post a Comment